Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




The Reality of Medical Software Compliance



By Kent Matthies

January 19, 2010 | “It is estimated that 60% of the computer systems containing patient medical records currently in use within the United States are not in compliance with the industry standards for security, audit trails, and electronic signatures,” states industry expert David Nettleton, FDA Compliance Specialist, of Computer System Validation.

With the Health Information Technology for Economic and Clinical Heath Act (HITECH Act) signed into law by President Obama last February, can health care organizations afford to be in that 60% group? The intent of the act is to use IT to improve health care quality and save money, while also strengthening privacy and security laws to protect the health information from misuse. The act provides both incentives for adopting meaningful electronic health records (EHRs) and penalties for not adopting EHRs. Furthermore, the HITECH Act now gives Health and Human Services (HHS) the ability to impose stiffer penalties for Health Insurance Portability and Accountability Act (HIPAA) violations.

The HITECH Act provides for $19 billion in grants and loan funding for incentives for the use of health information technology (HIT). Funds are intended for HIT infrastructure, training, implementation of best practices, and so on. Doctors and hospitals that have plans in place by 2011 are eligible for bonus payments under Medicare and Medicaid programs (bonuses will start to be phased out in 2014). Starting in 2015, health care providers that have not implemented an EHR could see their Medicare payments reduced by one percent, with the amount increasing to five percent by 2018.

The HITECH Act also finally puts some teeth behind HIPAA by providing strong notification of breach language and HHS can impose stiff penalties for HIT violations. Before the act, HIPAA violations could not exceed $100 per violation or $25,000 for all violations of the same provision. Now, violations can range up to $50,000 per violation or $1.5 million for all violations of the same provision. Civil penalties can only be barred by the health care provider if the health care provider corrects unknown violations of HIPAA regulations within 30 days of discovery.

So, although health care providers need to get on the band wagon, they should not do so blindly. The EHR must demonstrate meaningful use that supports compliance with federal and state regulations. Although not yet finalized, meaningful use requires an EHR to be considered certified. That is, it must include patient demographic and clinical health data and have the ability to support clinical decisions, support order entry, record data relevant to health care quality, and exchange and integrate electronic data from other sources. On top of this, the EHR is expected to include electronic prescriptions and must be able to submit clinical quality measures to HHS.

The onus lies on the health care provider, not the software vendor, to ensure compliance with the HITECH Act when implementing an EHR. Health care providers should look for three key aspects from software vendors when researching an EHR:

• The vendor has standard operating procedures (SOP) that provide specific instructions governing both how the company operates and how the software development process is conducted. These SOPs ensure software development is not compromised. The vendor needs to prove the software is designed, developed, and tested using a disciplined, controlled, and fully documented quality assurance methodology.
• The vendor uses a Software Development Life Cycle (SDLC) and documentation process that addresses the requirements of HIPAA and other federal and state regulations such as Title 21 of the Code of Federal Regulations Part 11 and 201 CMR 17.00. These documents will prove that the guidelines and rules for the storage, copying, access, release, auditing, and validation of health information are being followed.
• The software itself contains specific software features, based on current industry standards which address HIPAA & Part 11 requirements, such as patient confidentiality measures, data integrity checks, data security, audit trails, and electronic signatures that include valid statements of intent.

Organizations that are using or are planning to use EHRs should be among the 40% who are compliant. With new standards coming into legislation each year, no health care company needs to experience the ramifications that occur when using software that does not support compliance.

Kent Matthies is a Project Manager with SageKey Software, a Canadian company which specializes in building custom software for the medical industry. 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .